Navigation Links
Promising results shown for kidney cancer drug

The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma (RCC), a form of kidney cancer, in patients by 54% percent, according to a new study published in the Journal of Clinical Oncology.

"Advanced renal cell carcinoma remains a challenging disease, but the outlook for patients has improved in the past year including the addition of pazopanib, which targets multiple pathways within cancer cells," study author Dr. Cora N. Sternberg, chief of the medical oncology department at the San Camillo and Forlanini Hospital in Rome, Italy, said in a news release from the American Society of Clinical Oncology.

Dr. Sternberg also serves as the director of the scientific advisory board for the Columbus Cancer Foundation (, a international nonprofit organization devoted to supporting basic cancer research.

Pazopanib inhibits the development of blood vessels that tumors need to grow and spread.

"These clinical findings are indeed very encouraging," said Dr. Antonio Giordano, M.D., Ph.D., the founder and director of the Sbarro Health Research Organization located at Temple University in Philadelphia, PA. "We will look forward to the further studies which are currently evaluating the impact of pazopanib on the overall survival of treated patients."

In a phase 3 study, 233 patients with previously untreated locally advanced or metastastic kidney cancer and 202 other patients with kidney cancer who had been previously treated with interleukin or interferon, were randomly assigned to receive the oral drug pazopanib or a placebo.

Results showed that the time it took for a patient's disease to progress was more than double for the group receiving pazopanib (9.2 months), compared with the placebo group (4.2 months). The most dramatic effect was seen in previously untreated patients (11.1 months for the pazopanib group vs. 2.8 for the placebo) and persisted among those previously treated (7.4 vs. 4.2 months, respectively). The study is ongoing to determine how the drug impacts overall survival.

Common side effects of pazopanib included diarrhea (52 percent), hypertension (40 percent), hair color changes (38 percent), nausea (26 percent), weight loss (22 percent) and vomiting (21 percent).


Contact: Ilene Rush
Sbarro Health Research Organization

Related biology news :

1. UIC researchers find promising new targets for antibiotics
2. New book defines promising young field of adult neurogenesis
3. Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
4. Cancer and arthritis therapy may be promising treatment for diabetes
5. Unique whey protein is promising supplement for strict PKU diet
6. Promising new drug targets identified for Huntingtons disease
7. Promising new nanotechnology for spinal cord injury
8. Biodesigns Rittmann offers promising perspectives on societys energy challenge
9. UIC researchers make promising finding in severe lung disease
10. New treatment approach promising for lymphoma patients in the developing world
11. Immunotherapy in high-risk pediatric sarcomas shows promising response
Post Your Comments:
(Date:7/20/2017)... DAL ) customers now can use fingerprints instead of their ... (DCA). ... launches biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in May at ... process to allow eligible Delta SkyMiles Members who are enrolled in CLEAR ...
(Date:6/14/2017)... 15, 2017  IBM (NYSE: IBM ) is introducing several ... dedicated to developing collaboration between startups and global businesses, taking ... During the event, nine startups will showcase the solutions they ... industries. France is ... with a 30 percent increase in the number of startups ...
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
Breaking Biology News(10 mins):
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer ... first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With ... with the challenge of how to continue to feed a growing nation. At the ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree ... products targeting the needs of consumers who are incorporating medical marijuana into their ... Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... and applications consulting for microscopy and surface analysis, Nanoscience Instruments is now ... Analytical offers a broad range of contract analysis services for advanced applications. ...
(Date:10/7/2017)... Oct. 6, 2017  The 2017 Nobel Prize ... scientists, Jacques Dubochet, Joachim Frank and ... cryo-electron microscopy (cryo-EM) have helped to ... structural biology community. The winners worked with systems ... routinely produce highly resolved, three-dimensional images of protein ...
Breaking Biology Technology: